AFRM heads into August earnings with the Street more bullish than it has been in months — yet the stock just posted its sharpest weekly loss since spring.
The analyst story is the standout this week, and the direction is unambiguous. Bernstein initiated coverage Wednesday with an Outperform rating and a $100 target. Goldman Sachs raised its target to $106 earlier in the month, keeping a Buy. JP Morgan lifted to $90, Wells Fargo to $96, Barclays initiated at $97 Overweight, TD Cowen went to $117, and Citigroup pushed to $115. The consensus mean price target now sits at $89.90 — roughly 20% above Tuesday's close of $74.72. That kind of gap between where the stock trades and where the Street has it pencilled in is a genuine tension worth flagging. The key debate among bulls is the Affirm Bank initiative: if the industrial loan company charter comes through, funding costs fall and EPS estimates move up. Bears counter that competition is intensifying, macro headwinds could slow consumer credit growth, and any ILC rejection closes that optionality overnight.
Short positioning tells a much quieter story. Short interest is at 6.3% of the free float — meaningful, but trending down. It has fallen roughly 5% over the past week and about 4.5% over the past month, reaching 18.1 million shares. Short sellers are not pressing into this setup. The borrow market confirms that reading: cost to borrow is near 0.49%, among the cheapest levels of the past 30 days, and availability is loose at 615% — meaning there are roughly six shares available to borrow for every one already lent out. Nothing in the lending market suggests any squeeze dynamic is building.
Options positioning has grown modestly more defensive. The put/call ratio is running at 1.15, about one standard deviation above its 20-day average of 1.10. That's elevated relative to recent norms but nowhere near the 52-week high of 1.23. The shift higher has been gradual since late June, when the PCR was closer to 1.03. Taken together, shorts are retreating while options traders have added a thin layer of downside protection — cautious hedging rather than outright bearishness.
Institutional ownership adds an interesting layer. Capital Research added 5.5 million shares in the quarter to June 30, lifting its position to 14.2% of the company. FMR (Fidelity) added 3.2 million shares in the same period. JP Morgan Asset Management nearly doubled its position, adding 2.8 million shares. These are not passive index flows — these are active managers making directional bets at prices not far from where the stock trades today. Founder Max Levchin remains the second-largest holder at 8.1%. On the insider side, the COO sold $8 million of stock in late June at $80, which is worth noting — though routine tax-planning sales on RSU vesting are common at this level and the significance score was low.
On valuation, the stock's P/E multiple has compressed about 3.6 points over the past month to 17.5x, while EV/EBITDA has pulled back 5.2 points to 17.7x. The 30-day compression tracks the 11.5% weekly selloff — the stock was in the low $80s earlier this month. EPS momentum factor scores are exceptionally strong, ranking in the 98th and 96th percentile on 30-day and 90-day readings. Yet forward EPS growth expectations rank in just the 26th percentile, a reminder that near-term beat momentum and longer-term growth expectations are telling different stories. Among correlated peers, LDI fell 6.3% on the week and RKT dropped 4.5%, suggesting some of this week's pressure was sector-wide rather than AFRM-specific.
The next focal point is the August 25 earnings release — the most direct test of whether the Street's $90+ consensus has fundamental support, or whether the gap between analyst targets and the current price represents optimism that needs to be earned.
See the live data behind this article on ORTEX.
Open AFRM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
